BRIGHT MINDS BIOSCIENCES INC. (DRUG)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Drug Pipeline (1 Assets)

DrugPhaseIndications
FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE 		NDA Absence Epilepsy, Dravet Syndrome, Healthy, Jeavons Syndrome, Lennox-Gastaut Syndrome, Prader-Willi Syndrome

Upcoming Catalysts

DateEventDrug
2026-11-01 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06401538 BMB-101 in Absence Epilepsy and DEE PHASE2 Recruiting 20

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for DRUG.

SEC EDGAR Filings

All SEC filings for BRIGHT MINDS BIOSCIENCES INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.